| Gene | Score gda | Association Type | Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
0.060 | GeneticVariation | phenotype | BEFREE | In total, 26 patients (ST, n = 19; HCC, n = 7) were treated with pimasertib in Part 1: 30 mg (ST, n = 4; HCC, n = 5), 45 mg (ST, n = 9; HCC, n = 2), and 60 mg (ST, n = 6). | 31482223 | 2019 | ||||
|
0.060 | Biomarker | phenotype | BEFREE | <b>Purpose:</b> This large two-part, three-arm phase I study examined the safety and tolerability of CC-486 (an oral formulation of azacitidine, a hypomethylating agent) alone or in combination with the cytotoxic agents, carboplatin or nab-paclitaxel, in patients with advanced unresectable solid tumors.<b>Patients and Methods:</b> Part 1 (<i>n</i> = 57) was a dose escalation of CC-486 alone (arm C) or with carboplatin (arm A) or nab-paclitaxel (arm B). | 29764853 | 2018 | ||||
|
0.060 | Biomarker | phenotype | BEFREE | This phase I-II study was the first to evaluate single-agent oral rucaparib at multiple doses.<b>Experimental Design:</b> Part 1 (phase I) sought to determine the MTD, recommended phase II dose (RP2D), and pharmacokinetics of oral rucaparib administered in 21-day continuous cycles in patients with advanced solid tumors. | 28264872 | 2017 | ||||
|
0.060 | Biomarker | phenotype | BEFREE | Novel and Expanded Oncology Drug Approvals of 2016-PART 1: New Options in Solid Tumor Management. | 28205191 | 2017 | ||||
|
0.060 | Biomarker | phenotype | BEFREE | Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. | 28777142 | 2017 | ||||
|
0.060 | Biomarker | phenotype | BEFREE | To evaluate the safety (including adverse events and dose-limiting toxicities [DLTs]), tolerability, pharmacokinetics and antitumor activity of the investigational MET inhibitor rilotumumab alone in patients with advanced solid tumors (Part 1) or in combination with cisplatin plus capecitabine (CX) in patients with MET-positive advanced gastric or gastroesophageal junction cancer (Part 2). | 28973403 | 2017 |